Balaji Prasad
Stock Analyst at Barclays
(0)
# 3963
Out of 5,240 analysts
153
Total ratings
37.72%
Success rate
-3.90%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Revance Therapeutics | Maintains: Equal-Weight | 7 3 | 3.29 | -8.81% | 9 | Dec 23, 2024 | |
Teva Pharmaceutical ... | Maintains: Overweight | 25 28 | 21 | 33.33% | 11 | Dec 18, 2024 | |
Ligand Pharmaceutica... | Maintains: Overweight | 150 160 | 108.66 | 47.25% | 15 | Dec 16, 2024 | |
Phibro Animal Health | Maintains: Underweight | 13 20 | 20.3 | -1.48% | 7 | Nov 12, 2024 | |
Pacira BioSciences | Maintains: Equal-Weight | 25 17 | 20.55 | -17.27% | 8 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 11 12 | 11.71 | 2.48% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 19 20 | 11.69 | 71.09% | 12 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 18 17 | 15.28 | 11.26% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 570 481 | 418.22 | 15.01% | 8 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 20 16 | 9.45 | 69.31% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 8 10 | 7.86 | 27.23% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 230 242 | 164.36 | 47.24% | 14 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 22 18 | 13.33 | 35.03% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 50 60 | 44.3 | 35.44% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 230 200 | 123.1 | 62.47% | 6 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 8 7 | 1.45 | 382.76% | 7 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 3 10 | 3.09 | 223.62% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 28 | 15.84 | 76.77% | 1 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 3 2 | n/a | n/a | 2 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 26 21 | n/a | n/a | 4 | May 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 2 1 | n/a | n/a | 3 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 10 | n/a | n/a | 4 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 5 3 | n/a | n/a | 1 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 8 | n/a | n/a | 1 | Mar 25, 2020 |